FRA
IONS icon

Frank Rimerman Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Frank Rimerman Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$434K Hold
5,781
– – 0.03% 410
2025
Q4 		$457K Buy
5,781
+16
+0.3% +$1.21K 0.03% 402
2025
Q3 		$377K Buy
5,765
+2
+0% +$98 0.02% 424
2025
Q2 		$228K Buy
+5,763
New +$189K 0.02% 517

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Frank Rimerman Advisors's IONS Position: Q1 2026 in Review

Frank Rimerman Advisors held its Ionis Pharmaceuticals (IONS) position steady in Q1 2026 at 5,781 shares worth $434K. The position accounts for 0.03% of the portfolio, ranked #410.

Frank Rimerman Advisors first reported a position in IONS in Q2 2025 and has held it in 4 quarters since. The position peaked at $457K in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Frank Rimerman Advisors held 5,781 shares of Ionis Pharmaceuticals worth $434K as of Q1 2026.
  • Frank Rimerman Advisors left its Ionis Pharmaceuticals share count unchanged in Q1 2026.
  • Ionis Pharmaceuticals made up 0.03% of Frank Rimerman Advisors's portfolio in Q1 2026, its #410 holding.
  • Frank Rimerman Advisors first reported a position in Ionis Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Frank Rimerman Advisors's Ionis Pharmaceuticals position peaked at $457K in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Frank Rimerman Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.